Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Maintenance Treatment ◽

Controlled Trial ◽

Phase 3 ◽

Cancer Group ◽

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30862-9 ◽

2020 ◽

Vol 21 (4) ◽

pp. 497-507 ◽

Cited By ~ 28

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30027-0 ◽

2019 ◽

Vol 20 (6) ◽

pp. 849-861 ◽

Cited By ~ 74

Author(s):

Cathy Eng ◽

Tae Won Kim ◽

Johanna Bendell ◽

Guillem Argilés ◽

Niall C Tebbutt ◽

...

Keyword(s):

Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated ◽

A phase II double blind, randomised controlled trial of VEGF inhibitor axitinib monotherapy with early dynamic conrast enhanced ultrasound monitoring in chemorefractory third line metastatic colorectal cancer

http://isrctn.org/> ◽

10.1186/isrctn70833965 ◽

2013 ◽

Author(s):

Mohana Suppiah

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Controlled Trial ◽

Double Blind ◽

Vegf Inhibitor ◽

Ultrasound Monitoring ◽

Third Line ◽

Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(18)30269-3 ◽

2018 ◽

Vol 3 (12) ◽

pp. 845-855 ◽

Cited By ~ 5

Author(s):

Alvaro Romera ◽

Sergiy Peredpaya ◽

Yaroslav Shparyk ◽

Igor Bondarenko ◽

Giovanni Mendonça Bariani ◽

...

Keyword(s):

Colorectal Cancer ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Randomised Controlled ◽

First Line Treatment

Best available evidence related to clinical benefit of surgical resection in multimodality treatment of metastatic colorectal cancer indicates that a randomised controlled trial is warranted

European Journal of Cancer ◽

10.1016/j.ejca.2016.11.033 ◽

2017 ◽

Vol 75 ◽

pp. 310-312

Author(s):

Tom Treasure ◽

Norman R. Williams

Keyword(s):

Colorectal Cancer ◽

Surgical Resection ◽

Clinical Benefit ◽

Controlled Trial ◽

Multimodality Treatment ◽

Faculty Opinions recommendation of Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1166102.628092 ◽

2009 ◽

Author(s):

Jim Orr ◽

Fadi Abu Shahin

Keyword(s):

Ovarian Cancer ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽

Faculty Opinions recommendation of Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13827960.15267062 ◽

2012 ◽

Author(s):

Weijing Sun ◽

Davendra Sohal

Keyword(s):

Gastric Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

D2 Gastrectomy ◽

Faculty Opinions recommendation of Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3801959.6624054 ◽

2010 ◽

Author(s):

Atul Kumar ◽

Bhawna Halwan

Keyword(s):

Colorectal Cancer ◽

Flexible Sigmoidoscopy ◽

Controlled Trial ◽

Faculty Opinions recommendation of Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964810.793469147 ◽

2013 ◽

Author(s):

Yiqian Nancy You ◽

Brian Keith Bednarski

Keyword(s):

Colorectal Cancer ◽

Cancer Risk ◽

Resistant Starch ◽

Controlled Trial ◽

Hereditary Colorectal Cancer ◽

Term Effect ◽

Long Term Effect ◽